普通牛奶中的A1 β-酪蛋白会释放β-酪啡肽-7，从而引发肠道炎症、减慢肠道转运并加重症状（2016年的一项随机对照试验已证明）。
原始表述
يُضاف لذلك بروتين بيتا-كازين A1 في الحليب التقليدي، الذي أثبتت تجربة Nutrition Journal عام 2016 أنه يُنتج ببتيد بيتا-كازومورفين-7 المسبّب لالتهاب الأمعاء وبطء الحركة الهضمية.
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
普通牛奶中的A1 β-酪蛋白会释放β-酪啡肽-7，从而引发肠道炎症、减慢肠道转运并加重症状（2016年的一项随机对照试验已证明）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (eltayebat.com, rule 'dairy')
- 出处
- https://eltayebat.com/rule/dairy/
- 归属的不确定性
- Editorial narrative and study selection by the archive operators, not shown to be Elawady's own words; the archive homepage says the forbidden section is documented 'independently of Dr. Diaa's words'.
- 所声称的机制
Opioid peptide beta-casomorphin-7 from A1 beta-casein digestion.
- 所声称的健康影响
Gut inflammation, delayed transit, digestive discomfort, slower cognition.
- 涉及人群
People with self-reported milk intolerance (trial population); archive generalises.
- Elawady 设定的地域限制
none found
科学评估
不明确 / 证据不足 – 现有数据无法支持任何方向的评估。
证据确定性: 低 – 进一步研究很可能大幅改变该评估。
1. 说法是什么？
A1 beta-casein causes gut inflammation and slow transit via BCM-7.
2. 哪些内容可证实是正确的？
A-DRY-10 found more digestive symptoms (bloating, flatulence), longer colonic (+6.6 h) and whole-gut (+6.3 h) transit and higher IL-4, IgE and IgG with A1+A2 milk vs A2-only milk in Chinese adults with self-reported intolerance. An independent systematic review (I-DRY-04, GRADE) concluded 'moderate certainty for adverse digestive health effects of A1 beta-casein compared with A2'. In lactose-intolerant women, A2 milk caused fewer symptoms in a small trial (I-DRY-116).
3. 哪些内容是错误或夸大的？
A-DRY-10 was designed and funded by The a2 Milk Company; 2-week periods; 45 participants; no adjustment for multiple testing; beta-casomorphin-7 concentrations are claimed in the abstract but not reported in the results, so 'shown in a 2016 randomised trial' is not verifiable. Newer blinded trials did not confirm the effects: no differences in symptoms, transit (measured by ingestible sensor) or IgG, IgE, IL-4 (I-DRY-114, n=50), and no difference between A2 and A1 milk in lactose-tolerant people, with no rise in calprotectin or hs-CRP during milk periods (I-DRY-115). Lactose appears to explain much of the discomfort. The comparison is A1 vs A2 milk, not milk vs no milk, and cheese contains the same caseins.
4. 哪些内容仍不明确？
Whether BCM-7 effects in fermented/aged cheese differ; effects beyond symptoms.
5. 哪些研究支持该说法？
A-DRY-10 (symptoms and transit; BCM-7 data not reported; high risk of bias); I-DRY-04 (digestive symptoms, moderate certainty); I-DRY-05 (industry-linked review); I-DRY-116 (benefit only in lactose-intolerant women).
6. 哪些研究与该说法相矛盾？
I-DRY-114 (blinded RCT: no differences in symptoms, transit or immune markers); I-DRY-115 (A2 v A1 no difference in lactose-tolerant people; no rise in calprotectin/hs-CRP); I-DRY-04 (most RCTs on intermediate markers found no difference).
7. 对德国和欧洲而言情况如何？
EFSA reviewed beta-casomorphins in 2009 (report could not be accessed for this review; not used).
8. 关于埃及的已知情况是什么？
Egyptian cow and buffalo milk A1/A2 composition not examined here.
9. 合理的实际结论是什么？
有些人，尤其是乳糖吸收不良的人，喝A2牛奶或无乳糖牛奶可能会感觉更好；这是个人耐受性的问题，不能成为禁止鲜牛奶、却允许富含酪蛋白的奶酪的理由。
评估详情
- 证据确定性的依据
Earlier, mostly industry-funded trials (A-DRY-10, summarised in I-DRY-04/I-DRY-05) reported more digestive symptoms with A1 than A2 milk, but newer blinded crossover trials found no differences in symptoms, gut transit or inflammation markers (I-DRY-114, sponsored by an A2 milk company; I-DRY-115), and one trial found an A2 benefit only in lactose-intolerant women (I-DRY-116). The key 2016 trial does not report its beta-casomorphin-7 results and is at high risk of bias. The evidence is conflicting and of low certainty.
- 来源质量
Archive editorial; 'proved' (أثبتت) overstates a single 45-person, industry-funded crossover trial.
- 地区可推广性
Trial in Han Chinese adults with self-reported lactose intolerance; transfer to other populations uncertain.
- 个体例外情况
People who tolerate milk poorly may test A2 milk; this is an individual intolerance issue.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Does A1 beta-casein in conventional milk cause gut inflammation, slower transit and more symptoms compared with A2-only milk?
研究问题详解 (PICO)
- 人群
- Adults, including those with self-reported milk intolerance
- 干预或暴露
- Conventional (A1+A2) milk
- 对照
- A2-only milk
- 地域范围
- universal biology
- 结局指标
- GI symptoms
- Transit time
- Inflammatory markers (calprotectin, hs-CRP, cytokines)
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Small company-funded trial: A2 milk caused fewer stomach complaints
Chinese crossover RCT (industry-funded): more symptoms, longer transit and higher some immune markers with A1+A2 milk.
- 实际结果
- Colonic transit +6.6 h; whole-gut +6.3 h (existing).
- 方法学质量
- low (high risk of bias, selective reporting)
- 相关性
- direct
- 局限
- BCM-7 data not reported; 45 participants.
Independent review: A1 milk may upset digestion, other effects unproven
Systematic review: moderate certainty for adverse digestive effects of A1 v A2.
- 实际结果
- GRADE moderate for digestive symptoms (existing).
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Mostly industry-funded small trials.
A2 milk helped only lactose-intolerant women
In 10 lactose-intolerant women, A2 milk caused fewer symptoms than conventional milk.
- 实际结果
- Nausea 8 v 15 mm; breath H2 59 v 98 ppm.
- 方法学质量
- low
- 相关性
- direct
- 局限
- Tiny subgroup; no effect in other intolerant women.
哪些证据不支持该说法？
A2 milk no better than ordinary milk in a US trial
Double-blind crossover RCT (n=50, sponsored by The a2 Milk Company): no differences in symptoms, transit or immune markers.
- 实际结果
- All primary outcomes non-significant.
- 方法学质量
- moderate (pilot RCT)
- 相关性
- direct
- 局限
- No power calculation.
Lactose, not the A1 protein, explained milk symptoms
Randomised crossover: A2 and hydrolysed A1A2 milk equally tolerated in lactose-tolerant people; calprotectin and hs-CRP not raised by milk.
- 实际结果
- No difference; lactose drove symptoms.
- 方法学质量
- low-moderate (small, 3-day periods)
- 相关性
- direct
- 局限
- Short.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Evidence for an A1-specific harm is inconsistent: earlier mostly industry-funded trials found more symptoms with A1, newer blinded trials found no differences in symptoms, transit or inflammation markers, and lactose seems to explain much of the discomfort.
为什么有些研究权重更大
Newer blinded crossover trials with objective measures are weighted equally with older positive trials; none is large.
因果关系是否已确立？ 尚未确立 Inconsistent trial results; BCM-7 not measured in the key trial.
仍存在的不确定性
Whether a subgroup (lactose malabsorbers) benefits from A2 milk.
合理的结论
The claim that A1 casein 'triggers gut inflammation' is not established; the 2016 trial did not prove it.
为什么研究结果看起来互相矛盾？
Positive trials enrolled Chinese adults with self-reported intolerance and were company-funded; null trials enrolled US/other adults and separated lactose effects. Population lactase status and lactose content likely explain the differences.
这是否取决于国家？
- 一般生物学效应
- Transferable.
- 本国生产条件
- A1/A2 composition of Egyptian cow and buffalo milk not examined.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Primary outcome significance – All primary outcomes non-significant; correlations exploratory (not recalculated). 无法根据已发表数据重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Digestive symptoms A1 v A2 milk
- 起始等级
- 高（随机试验）
- 降级理由
- risk of bias (industry funding, selective reporting)
- inconsistency
- imprecision
- 结果
- 低
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | ("A2"[tiab] AND "beta-casein"[tiab] OR "β-casein"[tiab] AND A2[tiab]) AND (randomized[tiab] OR randomised[tiab] OR crossover[tiab]) AND 2018:2026[dp] | 双向 | 21 |
待解决的问题
Large independent trials stratified by lactase status; BCM-7 measurements.
核查深度如何？
6 项相关研究：1 项核查了全文（其中 1 项进行了结构化偏倚风险评估），5 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 可能正确 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 可能正确 (低) → 不明确 / 证据不足 (低)
The evidence base changed: two newer blinded RCTs (I-DRY-114, I-DRY-115), one even sponsored by an A2 milk company, found no A1-specific effects on symptoms, transit or inflammation markers, and I-DRY-116 limits any benefit to lactose-intolerant people. The prior 'potentially true' rested mainly on industry-funded trials; the totality is now conflicting.
新来源: I-DRY-114 I-DRY-115 I-DRY-116
通俗解释
牛奶中含有一种名为β-酪蛋白的蛋白质，它有A1和A2两种形式。一项在中国开展、由一家A2牛奶公司资助的小型试验发现，喝普通牛奶比喝只含A2的牛奶出现更多胃部症状。其他国家较新的盲法试验则发现，两者在症状、肠道转运速度或炎症标志物方面没有差异，而大部分不适似乎可以用乳糖（奶中的糖）来解释。因此，A1蛋白是否有影响尚不明确，也没有可靠证据表明它会让肠道发炎。奶酪中含有同样的蛋白质。
与该说法相关的研究
支持该说法的研究 (2)
-
Small company-funded trial: A2 milk caused fewer stomach complaints
Jianqin S et al.. Nutr J 2016 · PMID 27039383 · DOI 10.1186/s12937-016-0147-z随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究People who felt milk did not agree with them had more symptoms with ordinary milk than with A2 milk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare A1+A2 vs A2-only milk.
- 研究是如何开展的？
Double-blind crossover, 2 weeks per milk.
- 研究了多少人、动物或样本？
45 Chinese adults with self-reported intolerance.
- 实际发现了什么？
More bloating, flatulence, longer colonic transit (+6.6 h) and small changes in immune markers with ordinary milk than with A2 milk; CRP unchanged; A2 milk caused no worsening.
- 观察到的效应有多大？
Colonic transit +6.6 h; IL-4 +2.5 ng/L; IgE +6 IU/mL; hs-CRP not significant.
- 研究结果对日常生活意味着什么？
Some people may tolerate A2 milk better.
- 该研究有哪些局限？
Funded and partly designed by the A2 milk company; small; 2 weeks; many outcomes; some planned measurements (BCM-7) not reported in main text.
- 它对 Elawady 的具体说法说明了什么？
Supports A1-vs-A2 differences, not avoiding dairy.
- 研究结果是否适用于德国和欧洲？
Low.
- 从该研究中明确不能得出什么结论？
That milk inflames everyone; that dairy should be avoided; that BCM-7 was shown to rise (not reported in main text).
-
Industry-linked review: A1 milk effects mostly shown in rodents
Brooke-Taylor S et al.. Adv Nutr 2017 · PMID 28916574 · DOI 10.3945/an.116.013953系统综述独立交叉核查已核查摘要Human evidence limited to a few studies.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
A1 vs A2 GI effects.
- 研究是如何开展的？
Review of 39 studies.
- 研究了多少人、动物或样本？
Mostly rodents.
- 实际发现了什么？
Effects in animals; little in humans.
- 观察到的效应有多大？
n/a
- 研究结果对日常生活意味着什么？
Weak evidence for people.
- 该研究有哪些局限？
COI; animal data.
- 它对 Elawady 的具体说法说明了什么？
Weak support.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Effects in humans in general.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (2)
-
A2 milk no better than ordinary milk in a US trial
Greenway FL et al.. Nutr J 2026 · PMID 41634798 · DOI 10.1186/s12937-026-01288-9随机对照试验独立交叉核查已核查摘要No differences in symptoms, gut transit or immune markers.
No differences in symptoms, transit or immune markers.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test A2 milk in people who feel unwell after milk.
- 研究是如何开展的？
Double-blind crossover RCT.
- 研究了多少人、动物或样本？
50 adults.
- 实际发现了什么？
No differences.
- 观察到的效应有多大？
No significant effects.
- 研究结果对日常生活意味着什么？
A1 protein may not be the cause of milk discomfort.
- 该研究有哪些局限？
Small pilot; company-sponsored.
- 它对 Elawady 的具体说法说明了什么？
Contradicts the claim.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot exclude small effects.
-
Lactose, not the A1 protein, explained milk symptoms
Mannila E et al.. J Dairy Sci 2025 · PMID 40614809 · DOI 10.3168/jds.2025-26712随机对照试验独立交叉核查已核查摘要No difference between A2 and A1 milk in lactose-tolerant people; no rise in inflammation markers.
No A1 v A2 difference in lactose-tolerant people; no rise in calprotectin/hs-CRP.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Separate lactose from A1 protein effects.
- 研究是如何开展的？
Crossover RCT.
- 研究了多少人、动物或样本？
36 adults.
- 实际发现了什么？
Lactose mattered; A1 did not.
- 观察到的效应有多大？
No significant differences.
- 研究结果对日常生活意味着什么？
Lactose-free milk may help sensitive people.
- 该研究有哪些局限？
Very short and small.
- 它对 Elawady 的具体说法说明了什么？
Contradicts A1-inflammation claim.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot rule out long-term effects.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (2)
-
Independent review: A1 milk may upset digestion, other effects unproven
Küllenberg de Gaudry D et al.. Nutr Rev 2019 · PMID 30722004 · DOI 10.1093/nutrit/nuy063系统综述独立交叉核查已核查摘要★ 关键研究Moderate certainty for digestive symptoms; low/very low for other outcomes.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
A1 casein and health.
- 研究是如何开展的？
Systematic review with GRADE.
- 研究了多少人、动物或样本？
25 human studies.
- 实际发现了什么？
Digestive effects moderately supported; others not.
- 观察到的效应有多大？
Not pooled.
- 研究结果对日常生活意味着什么？
Some people may digest A2 milk better.
- 该研究有哪些局限？
Small trials.
- 它对 Elawady 的具体说法说明了什么？
Partly supports C-DRY-07.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Systemic inflammation or disease.
-
A2 milk helped only lactose-intolerant women
Milan AM et al.. Am J Clin Nutr 2020 · PMID 31773165 · DOI 10.1093/ajcn/nqz279随机对照试验独立交叉核查已核查摘要Fewer symptoms with A2 milk in 10 lactose-intolerant women; no difference in others.
A2 benefit only in lactose-intolerant women.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Separate lactose and A1 effects.
- 研究是如何开展的？
Blinded crossover.
- 研究了多少人、动物或样本？
40 women.
- 实际发现了什么？
A2 helped lactose-intolerant women only.
- 观察到的效应有多大？
Nausea 8 v 15 mm.
- 研究结果对日常生活意味着什么？
A1 may matter for some lactose-intolerant people.
- 该研究有哪些局限？
Tiny groups; single meals.
- 它对 Elawady 的具体说法说明了什么？
Partly supports.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot show inflammation or long-term effects.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
EFSA reviewed beta-casomorphins in 2009 (report could not be accessed for this review; not used).
埃及
Egyptian cow and buffalo milk A1/A2 composition not examined here.
在我的国家适用什么？
一般科学评估
不明确 / 证据不足 A1 β-酪蛋白是否比A2引起更多消化不适尚不明确，也没有可靠证据表明它会引起肠道炎症；无论如何，这一发现涉及的都是不同种类的牛奶，而不是牛奶与奶酪的比较。
以下食品安全领域与该说法相关：
- 兽药与抗生素
- 激素类促生长剂
- 污染物（重金属、PFAS、PCB、二噁英、硝酸盐）
- 真菌毒素（霉菌毒素）
- 监管、进口、召回、标签
乳制品
选择一个国家，查看针对该国已核查的信息。
局限：法律规则描述的是允许什么，而不是每一种食品实际含有什么。检测数据来自样本，只有结合其方法细节才有意义。
参考文献
- Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk.. Jianqin S et al.. Nutr J 2016 · PMID 27039383 · DOI 10.1186/s12937-016-0147-z
- Systematic Review of the Gastrointestinal Effects of A1 Compared with A2 β-Casein.. Brooke-Taylor S et al.. Adv Nutr 2017 · PMID 28916574 · DOI 10.3945/an.116.013953
- Comparative effects of conventional cow's milk versus milk free of A1-type beta-casein on gastrointestinal physiology and symptoms of digestive discomfort in participants intolerant to conventional cow's milk: a pilot randomised controlled trial.. Greenway FL et al.. Nutr J 2026 · PMID 41634798 · DOI 10.1186/s12937-026-01288-9
- Tolerance of protein-hydrolyzed lactose-free A1 milk and A2 milk in lactose-tolerant and lactose-intolerant volunteers: A randomized crossover trial with 2 parallel groups.. Mannila E et al.. J Dairy Sci 2025 · PMID 40614809 · DOI 10.3168/jds.2025-26712
- Milk A1 β-casein and health-related outcomes in humans: a systematic review.. Küllenberg de Gaudry D et al.. Nutr Rev 2019 · PMID 30722004 · DOI 10.1093/nutrit/nuy063
- Comparison of the impact of bovine milk beta-casein variants on digestive comfort in females self-reporting dairy intolerance: a randomized controlled trial.. Milan AM et al.. Am J Clin Nutr 2020 · PMID 31773165 · DOI 10.1093/ajcn/nqz279